Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0311277 (
abdominal obesity
)
2,792
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Background Metabolic syndrome (MetS) and
migraine
are known to be associated. This study assessed the risk of MetS and its clinical characteristics in
migraine
with aura (MA) and without aura (MO) based on a large-scale cross-sectional survey. Methods The study material consisted of 751 participants in the Nutrition, Environment and CardioVascular Health (NESCaV) survey. Diagnosis of
migraine
was based on the ef-ID
migraine
questionnaire and MetS was defined according to the Revised-Adult Treatment Panel III criteria. Sociodemographic and risk factors were also recorded. Weighted logistic regression was used to assess the risk of MetS. Results After adjusting for stratification (gender, age, district) and other factors (smoking status, sedentary lifestyle, family history of stroke, myocardial infarction and hypertension), MA subjects were at higher risk of MetS (OR 3.45; 95% CI: 1.63-7.29) while MO individuals were not, when compared to non-migraineurs. When considering MetS components, MA was positively associated with low HDL-cholesterol (OR 2.26; 95% CI: 1.08-4.74), hyperglycemia (OR 2.77; 95% CI: 1.30-5.88) and
abdominal obesity
(OR 2.03; 95% CI: 1.07-3.86). Conclusion Migraineurs with aura are at higher risk of MetS, suggesting that these subjects, already more exposed to stroke, may benefit from a systematic screening for the metabolic syndrome.
...
PMID:Screening for the metabolic syndrome in subjects with migraine. 2770 95